MRK vs BIIB
By Alex · Tickerpine
Merck & Company, Inc. vs Biogen Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | MRK | BIIB |
|---|---|---|
| Price | $132.92 | $208.87 |
| Market cap | $327.94B | $30.86B |
| P/E ratio | 106.3 | 36.3 |
| ROE | 6.96% | 4.58% |
| Profit margin | 4.77% | 8.32% |
| Revenue growth | 5.10% | 3.40% |
| Dividend yield | 2.56% | — |
| Beta | 0.21 | 0.16 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
MRK vs BIIB in plain English
- MRK is the bigger company — about 10.6× the market cap of BIIB.
- BIIB is cheaper on earnings (P/E 36.3 vs 106.3).
- MRK earns a higher return on equity (7% vs 5%).
- MRK is growing revenue faster (5% vs 3%).
- MRK pays a dividend (2.56%) while the other effectively doesn't.
How would $1,000 have done in each?
MRK return calculator
See what $1,000 in Merck & Company, Inc. would be worth today.
BIIB return calculator
See what $1,000 in Biogen Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.